Bayer/GSK Levitra EU approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bayer/GlaxoSmithKline's erectile dysfunction therapy Levitra (vardenafil) receives marketing authorization in Europe, firms announce March 7. Approval of the PDE-5 inhibitor is based on clinical studies in 3,750 men. The Summary of Product Characteristics states that Levitra allows some men to attain an erection as early as 15 min. after dosing (25 min. for most men) and for up to nearly five hours after dosing, the firms say. The recommended starting dose of Levitra is 10 mg 25 to 60 min. before sexual activity. Vardenafil received a positive opinion from the European Committee for Proprietary Medicinal Products Nov. 21, 2002 (Pharmaceutical Approvals Monthly, Dec. 1, 2002, In Brief). Lilly ICOS' Cialis (tadalafil) beat Levitra to market with its Nov. 12, 2002 EU approval (see related story, p. 3). Tadalafil and vardenafil are both currently "approvable" at FDA, pending submission of additional short-term clinical pharmacology studies for each ED agen
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.